Definium Therapeutics Stock Performance
as on September 2, 2026 at 2:15 pm IST
Day's Low
Day's High
$38.15$40.00
0.91%
Downside
3.90%
Upside
52 Week's Low
52 Week's High
100.00%
Downside
-100.00%
Upside
Definium Therapeutics share price movements today
- Previous Close
- $39.72
- Open
- $39.38
- Volume
- 1.2M
- Market Cap
- $5.3B
- Day's Low - High
- $38.15 - $40.00
Definium Therapeutics Historical Returns
- 1 Month Return
- -11.53 %
- 3 Month Return
- + 68.42 %
- 1 Year Return
- 0 %
- 3 Year Return
- 0 %
- 5 Year Return
- 0 %
Definium Therapeutics Stock Fundamentals & Key Indicators
Check Definium Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$5.3B
EPS (TTM)
-3.44
Dividend Yield
0.00%
PE Ratio (TTM)
-13.03
Industry PE ratio
-13.558214285714286
PEG Ratio
0.17608489402767594
Return On Equity TTM
-85.23%
Definium Therapeutics Stock Valuation
Track how Definium Therapeutics P/E has moved over time to understand its valuation trends.
Definium Therapeutics in the last 5 years
Lowest (-6.50x)
December 31, 2025
Industry (-13.56x)
December 31, 2025
Today (-6.50x)
December 31, 2025
Highest (-1.20x)
December 31, 2022
Today’s Price to Earnings Ratio: -6.50x
Definium Therapeutics vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Definium Therapeutics with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % | Dividend Yield % |
|---|---|---|---|---|---|---|
| StrongBuy | $5.3B | NA | -13.03 | 0.00% | NA | |
| BUY | $44.6B | 614.61% | NA | 0.00% | NA | |
| BUY | $137.9B | 174.9% | 31.92 | 86.04% | NA | |
| BUY | $61.6B | -61.21% | -7.98 | -12.57% | NA | |
| BUY | $82.3B | 21.91% | 19.9 | 84.86% | 0.44% |
Analyst Recommendation on Definium Therapeutics Stock
Based on 15 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 15 analysts, 100% of analysts recommend a 'BUY' rating for Definium Therapeutics. Average target price of $66.87
Indian Investors' Interest in Definium Therapeutics Stock
Search interest for Definium Therapeutics Stock has increased by 9% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:9% versus previous 30 day period
Definium Therapeutics Quarterly Profit & Loss
All numbers in Millions USD
Definium Therapeutics Annual Profit & Loss
All numbers in Millions USD
Definium Therapeutics Quarterly Cash Flow
All numbers in Millions USD
Definium Therapeutics Annual Cash Flow
All numbers in Millions USD
Definium Therapeutics News & Key Events
Today's Timeline - 22 June
Mon, 04:42 PM
-Definium Therapeutics announces positive Phase 3 results for DT120 ODT in major depressive disorder, showing significant efficacy.
Insights on Definium Therapeutics
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTBest in 3 Years
In the last 3 years, DFTX has outperformed top 5 stocks with highest market-cap in its industry
NO EFFECTAgainst Peers
In the last 1 year, Moderna, Inc. Common Stock has given 537.7% return, outperforming this stock by 216.0%
NEGATIVE IMPACTPrice Dip
In the last 7 days, DFTX stock has moved down by -12.0%
About Definium Therapeutics
| Organisation | Definium Therapeutics |
| Headquarters | One World Trade Center, New York, NY, United States, 10007 |
| Industry | Biotechnology |
| CEO | Mr. Robert Barrow |
| E-voting on shares | Click here to vote |
Key Management of Definium Therapeutics
Name | Title |
|---|---|
Ms. Gitanjali Jain Ogawa | VP & Head of Investor Relations |
Ms. Beth Calitri | Vice President of Corporate Communications |
Ms. Brandi L. Roberts CPA, M.B.A. | Chief Financial Officer |
Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer |
Dr. Scott M. Freeman M.D. | Co-Founder & Clinical Advisor |
Mr. Leonard Latchman | Co-Founder |
Mr. Peter Mack | Senior Vice President of Pharmaceutical Development & Operations |
Mr. Robert Barrow | CEO & Director |
Mr. Mark R. Sullivan J.D. | Chief Legal Officer & Corporate Secretary |
Ms. Stephanie Fagan M.S. | Chief Corporate Affairs Officer |
FAQs
What is Definium Therapeutics share price today?
Definium Therapeutics share price today is $38.50 as on at the close of the market. Definium Therapeutics share today touched a day high of $40.00 and a low of $38.15.
What is the 52 week high and 52 week low for Definium Therapeutics share?
Definium Therapeutics share touched a 52 week high of $0.00 on and a 52 week low of $0.00 on . Definium Therapeutics stock price today i.e. is closed at $38.50,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.
What is Definium Therapeutics's market capitalisation today?
Definium Therapeutics market capitalisation is $0.01T as on .
How to invest in Definium Therapeutics Stock (DFTX) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Definium Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Definium Therapeutics Shares that will get you 0.0390 shares as per Definium Therapeutics share price of $38.50 per share as on September 2, 2026 at 8:45 am IST.
What is the minimum amount required to buy Definium Therapeutics Stock (DFTX) from India?
Indian investors can start investing in Definium Therapeutics (DFTX) shares with as little as ₹94.96 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.60 in Definium Therapeutics stock (as per the Rupee-Dollar exchange rate as on ).
Based on Definium Therapeutics share’s latest price of $38.50 as on September 2, 2026 at 8:45 am IST, you will get 0.2597 shares of Definium Therapeutics. Learn more about
fractional shares .